Search

Author/Creator Farinola, Nicholas

1. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Issue 5 (4th May 2021)

Authors:
Aliprantis, Antonios O.; Shaw, Christine A.; Griffin, Paul; Farinola, Nicholas; Railkar, Radha A.; Cao, Xin; Liu, Wen; Sachs, Jeffrey R.; Swenson, Christine J.; Lee, Heather; Cox, Kara S.; Spellman, Daniel S.; Winstead, Colleen J.; Smolenov, Igor; Lai, Eseng; Zaks, Tal; Espeseth, Amy S.; Panther,...
Journal:
Human vaccines & immunotherapeutics
Issue:
Volume 17:Issue 5(2021)
Page Start:
1248
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing?. (February 2018)

Authors:
Farinola, Nicholas; Caughey, Gillian E.; Bell, J. Simon; Johns, Sally; Hauta-aho, Milka; Shakib, Sepehr
Journal:
Therapeutic advances in drug safety
Issue:
Volume 9:Number 2(2018)
Page Start:
113
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Issue 4 (4th March 2020)

Authors:
Leber, Andrew; Hontecillas, Raquel; Zoccoli-Rodriguez, Victoria; Colombel, Jean-Frederic; Chauhan, Jyoti; Ehrich, Marion; Farinola, Nicholas; Bassaganya-Riera, Josep
Journal:
Inflammatory bowel diseases
Issue:
Volume 26:Issue 4(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Issue 4 (11th May 2019)

Authors:
Leber, Andrew; Hontecillas, Raquel; Zoccoli-Rodriguez, Victoria; Colombel, Jean-Frederic; Chauhan, Jyoti; Ehrich, Marion; Farinola, Nicholas; Bassaganya-Riera, Josep
Journal:
Inflammatory bowel diseases
Issue:
Volume 26:Issue 4(2020)
Page Start:
643
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗